Compare Incyte Corporation (INCY) vs S&P500 ETF (SPY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs S&P500 ETF — how do they compare? Incyte Corporation trades at $121.06 (market cap $24.54B), while S&P500 ETF trades at $772.36. The key difference: S&P500 ETF is trading nearer its 52-week high, Incyte Corporation nearer its low. Which is the better fit depends on your goals.
| INCY | SPY | |
|---|---|---|
Market Cap | $24.54B | — |
Sector | Health | — |
52-Week High | $129.93 | $773.22 |
52-Week Low | $81.61 | $631.99 |
Enterprise Value | $20.04B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Incyte Corporation (INCY) trades at $120.79, down 0.63% today, but maintains a bullish technical trend with strong fundamental performance. The stock is near its 52-week high, supported by robust earnings beats in Q1 and Q2 2026, with revenue growth accelerating to $5.14 billion in 2025. Recent news highlights regulatory approvals for Opzelura in the EU and a raised 2026 revenue outlook following a favorable CMS settlement.
The outlook remains positive given strong analyst consensus (52% buy ratings) and a $122.82 price target, though risks include reliance on key products and competitive pressures. Earnings momentum and institutional accumulation suggest further upside, but investors should monitor execution on growth initiatives.
SPY, the SPDR S&P 500 ETF Trust, trades at $772.47, down 0.08% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The ETF's valuation metrics are not applicable as it tracks the S&P 500 index, and it announced a $1.90 dividend payable in July 2026. Recent news highlights the S&P 500 reaching record highs amid mixed sentiment, with some analysts cautioning on high valuations while others project further gains.
The outlook for SPY is cautiously optimistic, driven by strong market momentum and corporate earnings, but faces risks from elevated valuations and potential inflation pressures. Investment opportunity lies in broad U.S. equity exposure, while key risks include market volatility and economic data surprises.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About S&P500 ETF
The ETF is designed to track the performance of the securities and the stocks in the S&P 500 Index. To maintain the composition and weightings, the advisor adjusts the ETF from time to time to conform to periodic changes in the index target.
Read more on SPY →
